VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

The Janus Henderson Global Life Sciences Fund returned 0.99% and the MSCI World Health Care IndexSM returned 5.10% for Q1 ...

Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and ...

The data concerns its product VYKAT XR, an extended-release tablet designed to treat hyperphagia in individuals with Prader-Willi syndrome (PWS). The study findings indicated that patients with ...

"VYKAT™ XR is more than a product—it represents real hope for patients and families, and we're honored to help make it accessible." For the first time, individuals with PWS—who live with ...

About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment ...

Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...